91 research outputs found
Π€ΠΈΠ·ΠΈΠΊΠΎ-Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΠΌΡΡΠ°Π½ΡΠ½ΡΡ ΡΠΎΡΠΌ L-Π°ΡΠΏΠ°ΡΠ°Π³ΠΈΠ½Π°Π·Ρ ΠΈΠ· Rhodospirillum rubrum, ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΡ Π°Π½ΡΠΈΡΠ΅Π»ΠΎΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ
Rru_A3730 protein is a bacterial Rhodospirillum rubrum L-asparaginase (RrA), which is known by its anticancer activity. RrA variants with point amino acid substitutions in the region of 150 amino acids residues: RrA17N, K149E, RrAE149R, V150P, F151T, RrΠ17N, E149R, V150P, RrAE149R, V150P, showed antiproliferative properties, and also by their ability to suppress telomerase activity. This work is devoted to comparison of physical-chemical and catalytic properties of these mutant forms of RrA. It is shown that pH optimum is in the alkaline zone (8.5 β 9.3); L-glutaminase and D-asparaginase activity is respectively not more than 0.1% and 1.6% of L-asparaginase for all studied variants of RrA. The presence of the N17-terminal amino acid sequence MASMTGGQMGRGSSRQ of the capsid protein of bacteriophage T7 in the RrA structure leads to an increase in the thermal stability of mutant RrA analogues (from 50Β°C to 56Β°C) and their resistance to denaturation in the presence of 3 β 4 M urea. It is of Metal ions exhibit multidirectional effects on L-asparaginase activity of RrA. K+, Ca2+, Zn2+, Cs+, Co2+ in significantly affect the activity of L-asparaginase, while Mn2+, Cu2+, Fe3+ ions inhibit it. There was no correlation between antitelomerase (antiproliferative) activity and kinetic properties of mutant forms of L-asparaginase RrA.ΠΠ΅Π»ΠΎΠΊ Rru_A3730, ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠΉ ΠΊΠ°ΠΊ Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ L-Π°ΡΠΏΠ°ΡΠ°Π³ΠΈΠ½Π°Π·Π° Rhodospirillum rubrum, ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΡΠ΅Π΄ΡΡΠ²Π°, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ Π΅Ρ Π²Π°ΡΠΈΠ°Π½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ½ΡΠΌΠΈ Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡΠ½ΡΠΌΠΈ Π·Π°ΠΌΠ΅Π½Π°ΠΌΠΈ Π² ΡΠ°ΠΉΠΎΠ½Π΅ 150 Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡΠ½ΠΎΠ³ΠΎ ΠΎΡΡΠ°ΡΠΊΠ° (Π°.ΠΊ.ΠΎ.): RrA17N, K149E, RrAE149R, V150P, F151T, RrΠ17N, E149R, V150P, RrAE149R, V150P, ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΠ΅ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π°Π½ΡΠΈΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΡΠΌΠΈ ΡΠ²ΠΎΠΉΡΡΠ²Π°ΠΌΠΈ, Π½ΠΎ ΠΈ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡΡ ΠΏΠΎΠ΄Π°Π²Π»ΡΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅Π»ΠΎΠΌΠ΅ΡΠ°Π·Ρ. ΠΠ°Π½Π½Π°Ρ ΡΠ°Π±ΠΎΡΠ° ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΈΠ·ΠΈΠΊΠΎ-Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΊΠ°ΡΠ°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ²ΠΎΠΉΡΡΠ² ΡΡΠΈΡ
ΠΌΡΡΠ°Π½ΡΠ½ΡΡ
ΡΠΎΡΠΌ RrA. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π΄Π»Ρ Π²ΡΠ΅Ρ
ΠΈΠ·ΡΡΠ΅Π½Π½ΡΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² RrA ΡΠ ΠΎΠΏΡΠΈΠΌΡΠΌ Π½Π°Ρ
ΠΎΠ΄ΠΈΡΡΡ Π² ΡΠ΅Π»ΠΎΡΠ½ΠΎΠΉ Π·ΠΎΠ½Π΅ (8.5 β 9.3); L-Π³Π»ΡΡΠ°ΠΌΠΈΠ½Π°Π·Π½Π°Ρ ΠΈ D-Π°ΡΠΏΠ°ΡΠ°Π³ΠΈΠ½Π°Π·Π½Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠΎΡΡΠ°Π²Π»ΡΡΡ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, Π½Π΅ Π±ΠΎΠ»Π΅Π΅ 0.1% ΠΈ 1.6% ΠΎΡ L-Π°ΡΠΏΠ°ΡΠ°Π³ΠΈΠ½Π°Π·Π½ΠΎΠΉ. ΠΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ 17N-ΠΊΠΎΠ½ΡΠ΅Π²ΠΎΠΉ Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡΠ½ΠΎΠΉ ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ MASMTGGQQMGRGSSRQ ΠΊΠ°ΠΏΡΠΈΠ΄Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π±Π°ΠΊΡΠ΅ΡΠΈΠΎΡΠ°Π³Π° Π’7 Π² ΡΡΡΡΠΊΡΡΡΠ΅ RrA ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΠ΅ΡΠΌΠΎΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΡΡΠΈ ΠΌΡΡΠ°Π½ΡΠ½ΡΡ
Π°Π½Π°Π»ΠΎΠ³ΠΎΠ² RrA (ΠΎΡ 50Β°Π‘ Π΄ΠΎ 56Β°Π‘) ΠΈ ΠΈΡ
ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΡΡΠΈ ΠΊ Π΄Π΅Π½Π°ΡΡΡΠ°ΡΠΈΠΈ Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠΈ 3 β 4 Π ΠΌΠΎΡΠ΅Π²ΠΈΠ½Ρ. ΠΡΡΠ²Π»Π΅Π½ ΡΠ°Π·Π½ΠΎΠ½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΠΉ ΡΡΡΠ΅ΠΊΡ ΠΈΠΎΠ½ΠΎΠ² ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² Π½Π° L-Π°ΡΠΏΠ°ΡΠ°Π³ΠΈΠ½Π°Π·Π½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² RrA: ΠΈΠΎΠ½Ρ K+, Ca2+, Zn2+, Cs+, Co2+ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π½Π΅ Π²Π»ΠΈΡΡΡ Π½Π° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ L-Π°ΡΠΏΠ°ΡΠ°Π³ΠΈΠ½Π°Π·Ρ, Π΄ΠΎΠ±Π°Π²Π»Π΅Π½ΠΈΠ΅ ΠΈΠΎΠ½ΠΎΠ² Mn2+, Cu2+, Fe3+ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ. ΠΠ΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΠΌΠ΅ΠΆΠ΄Ρ Π°Π½ΡΠΈΡΠ΅Π»ΠΎΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ (Π°Π½ΡΠΈΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠΉ) Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΈ ΠΊΠΈΠ½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠ²ΠΎΠΉΡΡΠ²Π°ΠΌΠΈ ΠΌΡΡΠ°Π½ΡΠ½ΡΡ
ΡΠΎΡΠΌ L-Π°ΡΠΏΠ°ΡΠ°Π³ΠΈΠ½Π°Π·Ρ RrA
L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis
Objectives: The aim of this review was to compare the efficacy of asparaginase (ASP)-containing vs ASP-absent regimens in the first-line treatment of ENKTL patients. Methods: The PRISMA protocol was used to search PubMed and Embase for both controlled and uncontrolled studies of ASP or alternative chemotherapy (CT) for newly diagnosed ENKTL, published in English by March 2017. The regimens were compared to calculate relative risk (RR) with 95% confidence interval (CI) of the overall response rate (ORR), complete response (CR) or partial response (PR). Results: Out of 38 studies included, eight were controlled trials, with the pooled RR of ORR in stage I-II 1.54 (95% CI 1.34β1.77); stage I-IV 1.34 (95% CI 1.09β1.64). In stage III-IV CT combined with radiotherapy (RT), RR of ORR was 2.30 (95% CI 1.66β3.18). ASP was also superior in achieving CR. When all single arms combined, RR of ORR after CT with ASP was 1.52 (95% CI 1.38β1.67) in stage I-II (15 studies); 1.44 (95% CI 1.32β1.57) in all stages (29 studies); 1.31 (95% CI 1.24β1.38) and 1.66 (95% CI 1.18β2.34) in stages I-II and III-IV combined with RT, correspondingly. Conclusions: ASP-based CT significantly improved ORR and CR in patients with newly diagnosed both early-stage and advanced-stage ENKTL. Β© 2017 Informa UK Limited, trading as Taylor & Francis Group
L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis
Objectives: The aim of this review was to compare the efficacy of asparaginase (ASP)-containing vs ASP-absent regimens in the first-line treatment of ENKTL patients. Methods: The PRISMA protocol was used to search PubMed and Embase for both controlled and uncontrolled studies of ASP or alternative chemotherapy (CT) for newly diagnosed ENKTL, published in English by March 2017. The regimens were compared to calculate relative risk (RR) with 95% confidence interval (CI) of the overall response rate (ORR), complete response (CR) or partial response (PR). Results: Out of 38 studies included, eight were controlled trials, with the pooled RR of ORR in stage I-II 1.54 (95% CI 1.34β1.77); stage I-IV 1.34 (95% CI 1.09β1.64). In stage III-IV CT combined with radiotherapy (RT), RR of ORR was 2.30 (95% CI 1.66β3.18). ASP was also superior in achieving CR. When all single arms combined, RR of ORR after CT with ASP was 1.52 (95% CI 1.38β1.67) in stage I-II (15 studies); 1.44 (95% CI 1.32β1.57) in all stages (29 studies); 1.31 (95% CI 1.24β1.38) and 1.66 (95% CI 1.18β2.34) in stages I-II and III-IV combined with RT, correspondingly. Conclusions: ASP-based CT significantly improved ORR and CR in patients with newly diagnosed both early-stage and advanced-stage ENKTL. Β© 2017 Informa UK Limited, trading as Taylor & Francis Group
Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion
Objectives: The aim of this study is to compare the toxicity profiles of SMILE versus less intense L-asparaginase-containing regimens, CCRT or βsandwichβ RT+CT regimens. Methods: PRISMA protocol was used to search Pubmed and Embase for studies of treatment regimens for extranodal NK/T-cell lymphoma, nasal type (ENKTL) in English published before March 2018. Pooled data were grouped into five categories: A) CHOP-like regimens; B) Gemcitabine-based regimens; C) SMILE-like regimens; D) Concurrent and βsandwichβ RT +Β CT; and E) Methotrexate-based combinations. We pooled prevalence of selected adverse events from each study to calculate the weighted overall prevalence using meta-proportion in Stata. Results: Group C was the most toxic with the pooled neutropenia 72% (95 CI 64;80) and thrombocytopenia 48% (95% CI 40;55) prevalence. The use of Group D treatment regimens was associated with the lowest anemia (10% (95% CI 1;19)) prevalence. Group E was the least toxic with regard to thrombocytopenia (6% (95% CI 1;11). Conclusion: Our analysis confirms that SMILE regimen, which is current standard to treat advanced-stage ENKTL may be associated with more severe hematological toxicity compared to other L-asparaginase combinations, including methotrexate-based (AspaMetDex, MESA and MEDA) or gemcitabine-based (GELOX, PGEMOX, DDGP, GDL, GOLD, GLIDE) or CCRT-based regimens. Β© 2018, Β© 2018 Informa UK Limited, trading as Taylor & Francis Group
Homogeneous precipitation of magnesium phosphates from seawater solutions
International audienceHomogeneous (unseeded) nucleation of Mg phosphate from modified Ca-free seawater solutions was investigated at 20Β°C and pH of 8. Precipitated solid phase was characterized using chemical analysis, X-ray diffraction, scanning electron microscopy, and IR-spectroscopy. Effect of aqueous phosphate and ammonia concentrations and the intensity of stirring on the induction period time ( Ο) of Mg phosphates nucleation were studied. A linear relationship between logarithm of bobbierite (Mg 3(PO 4) 2 Β· 8H 2O) saturation index and log Ο was established with a slope close to 2. Aqueous NH 4+ (up to 0.002 M) has no effect on the nucleation kinetics and does not incorporate in the precipitated solid phase. Stirring of solution has a dramatic effect on nucleation kinetics: the induction period decreases by a factor of 100-10 000 in unstirred solutions compared to stirred ones. The relative diffusion/chemical reaction control mechanism of Mg phosphates precipitation from supersaturated solutions is discussed. It is shown that spontaneous inorganic precipitation of Mg-(ammonium) phosphates (struvite and bobbierite) in modern marine environment is impossible because of very sluggish kinetics
Experimental evaluation of synergism of cisplatin with L-lysine-Ξ±- oxidase
Synergism effects of cisplatin and L-lysine-Ξ±-oxidase (LO), while sequential (no interval) administration of drugs depends on the tumor model and duration of treatment. Synergism is identified at intraperitoneal daily (during 3 days) administration of cisplatin to experimental animals in single doses of 1.5 or 3.0 mg / kg and intravenously 5-fold after 48 h administration of LO and also administered intravenously in cumulative doses of 300-600 E / kg discretely, the first dose - doubled. Synergism of cisplatin and LO is showed by significant (p<0,05) therapeutic gain against cisplatin at such indicators as increased survival of mice with P388 tumor and increased inhibition of primary tumor melanoma B16
Experimental evaluation of synergism of cisplatin with L-lysine-Ξ±- oxidase
Synergism effects of cisplatin and L-lysine-Ξ±-oxidase (LO), while sequential (no interval) administration of drugs depends on the tumor model and duration of treatment. Synergism is identified at intraperitoneal daily (during 3 days) administration of cisplatin to experimental animals in single doses of 1.5 or 3.0 mg / kg and intravenously 5-fold after 48 h administration of LO and also administered intravenously in cumulative doses of 300-600 E / kg discretely, the first dose - doubled. Synergism of cisplatin and LO is showed by significant (p<0,05) therapeutic gain against cisplatin at such indicators as increased survival of mice with P388 tumor and increased inhibition of primary tumor melanoma B16
Oxidative Stress and Redox-Dependent Signaling in Prostate Cancer
Abstract: Tumor emergence and progression is complicated by the dual role of reactive oxygen species (ROS). Low concentrations of ROS are essential for many intracellular metabolic processes and cell proliferation, while excessive ROS generation disrupts the mechanisms of cancer suppression, leading to the cell damage and death. A long-term imbalance in the ROS/antioxidant ratio and upregulation of the ROS generation due to the reduced efficacy of the antioxidant defense system cause chronic oxidative stress resulting in the damage of proteins, lipid, and DNA molecules and cancer development. Numerous data demonstrate that prostate cancer (the most common cancer in males) is associated with the development of oxidative stress. However, the reasons for the emergence of prostate cancer, as well as changes in the redox signaling and cellular redox homeostasis in this disease, are still poorly understood. The review examines the role of prooxidant and antioxidant enzyme systems, the imbalance in their activity leading to the oxidative stress development, changes in the key components of redox signaling, and the role of microRNAs in the modulation of redox status of cancer cells in prostate cancer. Β© 2022, Pleiades Publishing, Ltd
Experimental study of the efficacy of L-lysine-a-oxidase Trichoderma CF. Aureoviride Rifai on models of xenografts of human tumors in athymic mice and evaluation of synergism with cisplatin or topoisomerase inhibitors
The effectiveness of L-lysine-alpha oxidase Trichoderma cf. Aureoviride Rifai BKMF-4268D (LO) on models of subcutaneous xenografts of human tumors in athymic mice as well as the effectiveness of combination therapy with known antitumor drugs: cisplatin, irinotecan, etoposide on models of P388 lymphocytic leukemia, Lewis lung (LLC) and B16 melanoma was evaluated. The intraperitoneal injection of LO in a discrete regime at doses of 150-75-75-75-75 E/kg demonstrated inhibition of growth of all studied xenografts of human tumors in athymic mice. The combination of irinotecan+LO on the LLC model gave a significant summative therapeutic benefit with an increase in mouse life expectancy up to 35%. Cisplatin and LO realized a significant (p <0.05) therapeutic benefit against cisplatin according to an additive increase in the survival rate of mice with P388, UPJ = 208% vs. 128%; increased inhibition of growth of the primary node of melanoma B16, TPOmax = 87% vs. 58%. The addition of LO to etoposide did not lead to a significant improvement in the effect on the P388 model. The sensitivity to LO model of colon cancer and the presence of synergism with platinum and irinotecan drugs made LO a promising agent for the study in treatment for colon cancer
Predictive value of <sup>18</sup>F-FDG accumulation in visceral fat activity to detect epithelial ovarian cancer metastases
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, with relapse occurring in about 70% of advanced cases with poor prognosis. The study aimed to assess functional visceral fat activity (VAT) evaluated by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) as a predictor of metastases in epithelial ovarian cancer. Methods: We assessed 53 patients with histologically confirmed EOC who underwent 18F-FDG PET/CT after a surgical treatment and courses of chemotherapy. Age, histology, stage, and tumor grade were recorded. Functional VAT was measured by maximum standardized uptake value (SUVmaJ using 18F-FDG PET/CT and tested as a predictor of later metastases in eight abdominal locations and pelvis cavity in the adjusted regression models. We also identified the best areas under the curve (AUC) for SUVmx with the corresponding sensitivity (Se) and specificity (Sp). Results: In both adjusted for regression models and ROC analysis, 18F-FDG accumulation in RE (cut-off SUVmax 1.18; Se 64%; Sp 64%; AUC 0.669; p=0.035) could predict later metastases in EOC patients, as opposed to age, sex, primary tumor location, tumor grade, and histology. Conclusions: VAT SUVmx is significantly associated with later metastases in EOC patients and can be used as their predictor.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ: ΠΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΡΠΉ ΡΠ°ΠΊ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² (Epithelial Ovarian Cancer, EOC) ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ, ΡΠ΅ΡΠΈΠ΄ΠΈΠ² ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΡ ΠΏΡΠΈΠΌΠ΅ΡΠ½ΠΎ Π² 70Β°% Π·Π°ΠΏΡΡΠ΅Π½Π½ΡΠΉ: ΡΠ»ΡΡΠ°Π΅Π² ΠΈ ΠΎΡΠ»ΠΈΡΠ°Π΅ΡΡΡ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ - ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²ΠΈΡΡΠ΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΆΠΈΡΠΎΠ²ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ (VAT) ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ·ΠΈΡΡΠΎΠ½Π½ΠΎ-ΡΠΌΠΈΡΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΠΈ Ρ 18F-ΡΡΠΎΡΠ΄Π΅Π·ΠΎΠΊΡΠΈΠ³Π»ΡΠΊΠΎΠ·ΠΎΠΉ, ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½Π½ΠΎΠΉ Ρ ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½ΠΎΠΉ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΠ΅ΠΉ (18F-FDG ΠΠΠ’/ΠΠ’) Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠ° ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ EOC. ΠΠ΅ΡΠΎΠ΄Ρ: ΠΠ°ΠΌΠΈ Π±ΡΡΠΈ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 53 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π²Π΅ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ EOC, ΠΊΠΎΡΠΎΡΡΠΌ Π±ΡΡΠ° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° I8F-FDG ΠΠΠ’/ΠΠ’ ΠΏΠΎΡΠ»Π΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΊΡΡΡΠΎΠ² Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΡΠ΅Π½ΠΊΠ΅ ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π»ΠΈΡΡ ΡΠ°ΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ, ΠΊΠ°ΠΊ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠΈΠΏ, ΡΡΠ°Π΄ΠΈΡ ΠΈ ΡΡΠ΅ΠΏΠ΅Π½Ρ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°. Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ VAT Π±ΡΡΠ° ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½Π° Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΡ (SUVmax) ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠΉ ΡΠΈΡΡΠΎΠ²ΠΎΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ Π½Π° ΡΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΎΠ½Π½ΡΡ
ΠΌΠΎΠ΄Π΅Π»ΡΡ
Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠ° ΠΏΠΎΠ·Π΄Π½ΠΈΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ² Π±ΡΡΡΠ½ΠΎΠΉ ΠΏΠΎΠ»ΠΎΡΡΠΈ ΠΈ ΠΌΠ°Π»ΠΎΠ³ΠΎ ΡΠ°Π·Π°. Π’Π°ΠΊΠΆΠ΅ Π±ΡΡΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Π½Π°ΠΈΠ»ΡΡΡΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΏΠ»ΠΎΡΠ°Π΄ΠΈ ΠΏΠΎΠ΄ ΠΊΡΠΈΠ²ΠΎΠΉ (AUC) Π΄Π»Ρ SUVmax Ρ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠ΅ΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ (Se) ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡΡ (Sp). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΠ°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ 18F-FDG Π² RE (SUVmax 1,18; Se 64%; Sp 64%; AUC 0,669; p=0,035), ΠΊΠ°ΠΊ ΠΏΡΠΈ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡΠΎΠ²ΠΊΠ΅ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΎΠ½Π½ΡΡ
ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ, ΡΠ°ΠΊ ΠΈ ΠΏΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ ROC-ΠΊΡΠΈΠ²ΠΎΠΉ, ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·ΡΠ²Π°ΡΡ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ·Π΄Π½ΠΈΠ΅ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Ρ, ΡΠ΅ΠΌ Π²ΠΎΠ·ΡΠ°ΡΡ, ΠΏΠΎΠ», Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, ΡΡΠ΅ΠΏΠ΅Π½Ρ ΡΠ°ΠΊΠ° ΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠΈΠΏ ΡΠ°ΠΊΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ EOC. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅: Π£ΡΠΎΠ²Π΅Π½Ρ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΡ SUVmax Π² VAT ΡΠ²ΡΠ·Π°Π½ Ρ ΠΏΠΎΠ·Π΄Π½ΠΈΠΌ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ·Π»Ρ, ΡΡΠΎ ΠΈΠΌΠ΅Π΅Ρ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΡΡ ΡΠ΅Π½Π½ΠΎΡΡΡ Π΄Π»Ρ Π²ΡΠ±ΠΎΡΠ° ΡΠ°ΠΊΡΠΈΠΊΠΈ ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ EOC
- β¦